Ixazomib Impurity 13 CAS 6334-18-5

Purity >95%In StockPharmacopoeial Impurity Standards
CAS No.6334-18-5
Molecular FormulaC7H4Cl2O
Molecular Weight175.01 g/mol
CategoryPharmacopoeial Impurity Standards / EP Impurities
AvailabilityIn Stock

Chemical Structure

Ixazomib Impurity 13 CAS 6334-18-5 chemical structure

Description

CATO manufactures Ixazomib Impurity 13 under ISO 17034:2016 accreditation with dual CNAS and ANAB accreditation. Each batch is characterized by orthogonal methods and supplied with a full Certificate of Analysis (COA), ensuring metrological traceability.

Ixazomib Impurity 13 (CAS 6334-18-5) is a certified pharmaceutical impurity reference standard with the molecular formula C7H4Cl2O and a molecular weight of 175.01 g/mol.

Ixazomib Impurity 13 (C7H4Cl2O) contains a hydroxyl group, an ether linkage, chlorine substitution, an aromatic ring system. Halogen substitution raises its density and boiling point; these physicochemical properties determine the optimal preparation and storage of its standard solutions. The presence of an aromatic ring or conjugated system gives the compound characteristic absorption bands in the UV-Vis region, making it well suited to UV or diode-array detection (DAD).

Recommended for quantitative analysis by HPLC, GC, LC-MS/MS, or GC-MS as an external calibration standard; it can also be used for spiked-recovery experiments, LOD/LOQ determination, and LC-MS/MS multiple-reaction-monitoring (MRM) calibration.

Physical & Chemical Properties

Molecular FormulaC7H4Cl2O
Molecular Weight175.01 g/mol
AppearanceOff-white to pale yellow crystalline powder. (slight halide-like odor, low volatility)
Purity>95%
StorageStore at 2-8°C, keep tightly closed to prevent evaporation
Solubility (reference)Soluble in methanol, acetonitrile, DMSO, water (slightly soluble)
StabilityMay oxidize slowly on prolonged air exposure
Degree of Unsaturation (DBE)5.0
UV AbsorptionUV-absorbing
Structural FeaturesAromatic ring present
CAS Registry Year (est.)1958
Halogen ContentCl-containing

Related Ixazomib Standards

Recommended Standards

Why CATO?